Karyopharm Therapeut
(KPTI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 145,237 | 146,033 | 157,074 | 209,819 | 108,085 |
| Cost of Goods | 6,007 | 4,942 | 5,213 | 3,402 | 2,705 |
| Gross Profit | 139,230 | 141,091 | 151,861 | 206,417 | 105,380 |
| Operating Expenses | 258,680 | 271,573 | 294,276 | 305,090 | 277,935 |
| Operating Income | -119,443 | -129,540 | -142,202 | -98,271 | -171,850 |
| Interest Expense | 37,422 | 23,823 | 24,996 | 26,046 | 27,140 |
| Other Income | 80,500 | 10,587 | 2,276 | 497 | 3,026 |
| Pre-tax Income | -76,365 | -142,776 | -164,922 | -123,820 | -195,964 |
| Income Tax | 57 | 323 | 369 | 268 | 309 |
| Net Income Continuous | -76,422 | -143,099 | -165,291 | -124,088 | -196,273 |
| Net Income | $-76,422 | $-143,099 | $-165,291 | $-124,088 | $-196,273 |
| EPS Basic Total Ops | -9.45 | -18.74 | -30.28 | -24.74 | -40.78 |
| EPS Basic Continuous Ops | -9.40 | -18.78 | -30.27 | -24.73 | -40.84 |
| EPS Diluted Total Ops | -13.94 | -18.74 | -30.28 | -24.74 | -40.78 |
| EPS Diluted Continuous Ops | -9.04 | -18.78 | -30.27 | -24.73 | -40.84 |
| EPS Diluted Before Non-Recurring Items | -13.94 | -18.74 | -30.29 | -24.74 | -40.78 |
| EBITDA(a) | $-115,238 | $-132,294 | $-141,594 | $-95,142 | $-161,388 |